Quantitative tissue proteomics of esophageal squamous cell carcinoma for novel biomarker discovery

Pawar, Harsh; Kashyap, Manoj Kumar; Sahasrabuddhe, Nandini A.; Renuse, Santosh; Harsha, H. C.; Kumar, Praveen; Sharma, Jyoti; Kandasamy, Kumaran; Marimuthu, Arivusudar; Nair, Bipin; Ramasamy, Sudha; Maharudraiah, Jagadeesha; Premalatha, Chennagiri Shrinivasamurthy; Kumar, K.V. Veerendra; Vijayakumar, M.; Chaerkady, Raghothama; Prasad, T. S. Keshava; Kumar, Rekha V.; Pandey, Akhilesh

doi:10.4161/cbt.12.6.16833

Cited by 105 publications

(97 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meanwhile, periostin expression was identified to be significantly higher in esophageal squamous cell carcinoma (ESCC) compared with adjacent non-neoplastic esophageal epithelium (13). mRNA profiling of ESCC tissues demonstrated an upregulation of periostin as high as 11-fold (13).…”

Section: Periostin In Esophageal Cancermentioning

confidence: 99%

Role of periostin in esophageal, gastric and colon cancer

et al. 2016

View full text Add to dashboard Cite

Abstract. Periostin, also known as osteoblast-specific factor 2, is a cell-adhesion protein with pleiotropic properties. The protein serves a vital role in the maintenance and development of tooth and bone tissue, in addition to cardiac development and healing. Periostin levels are increased in several forms of cancer, including pancreatic, ovarian, colon, lung, breast, gastric, thyroid, and esophageal head and neck carcinomas. The present review highlights the key role of periostin in tumorigenesis, particularly in increasing cell survival, invasion, angiogenesis, epithelial-mesenchymal transition and metastasis of carcinoma cells by interacting with numerous cell-surface receptors, including integrins, in the phosphoinositide 3-kinase-Akt pathway. In addition, periostin actively affects the canonical Wnt signaling pathway of colorectal tumorigenesis. The current review focused on the involvement of periostin in the development of colorectal, esophageal and gastric cancer.

show abstract

Section: Periostin In Esophageal Cancermentioning

confidence: 99%

Role of periostin in esophageal, gastric and colon cancer

et al. 2016

View full text Add to dashboard Cite

show abstract

“…FHL1 expression is inversely related to invasion and metastatic potential of cancer cells [32]. We observed downregulation of FHL1 in ESCC in both gene expression profiling as well as quantitative proteomics studies [3]. In quantitative tissue proteomics study, FHL1 was found to be 4-fold downregulated in ESCC as compared to the adjacent normals [3].…”

Section: Fhl1 Protein Expression Is Suppressed Inmentioning

confidence: 85%

“…We observed downregulation of FHL1 in ESCC in both gene expression profiling as well as quantitative proteomics studies [3]. In quantitative tissue proteomics study, FHL1 was found to be 4-fold downregulated in ESCC as compared to the adjacent normals [3]. The MS and the MS/MS data is shown in Fig.…”

Section: Fhl1 Protein Expression Is Suppressed Inmentioning

confidence: 98%

Evaluation of protein expression pattern of stanniocalcin 2, insulin-like growth factor-binding protein 7, inhibin beta A and four and a half LIM domains 1 in esophageal squamous cell carcinoma

Kashyap

Pawar

Keerthikumar

et al. 2013

CBM

Self Cite

View full text Add to dashboard Cite

Abstract. The pathogenesis of esophageal squamous cell carcinoma (ESCC) involves both genetic and environmental factors. Previously, we have carried out gene and protein expression profiling of ESCC using DNA microarrays and mass spectrometrybased quantitative proteomics, respectively. These studies resulted in identification of several potential biomarkers of ESCC, some with known reports of differential expression in the scientific literature and others that were novel observations from our studies. We report systematic validation of selected markers from our studies on a larger cohort of cancer tissue sections by immunohistochemical labeling of tissue microarrays. We have validated expression of insulin-like growth factor-binding protein 7 (IGFBP7), stanniocalcin 2 (STC2), inhibin beta A (INHBA) and four and a half LIM domains 1 (FHL1). Immunohistochemical labeling with anti-stanniocalcin 2 antibody demonstrated its overexpression in 132/140 (94%) cases, IGFBP7 showed overexpression in 127/140 (91%) cases and overexpression of INHBA was observed in 62/105 (59%) of ESCC cases. In contrast, FHL1 expression was observed only in 12/143 (8%) of ESCC cases suggesting its possible involvement in tumor suppression. These data suggest that IGFBP7, INHBA, STC2 and FHL1 might play an important role in ESCC tumorigenesis, which can be explored in future studies. Overall, our findings open up new avenues for development of novel therapeutics and/or diagnostic approaches in ESCC.

show abstract

“…Its silencing decreases proliferation, migration and invasion, which is attributed to reduced ERK phosphorylation [50][51][52]54,55]. Plectin can promote the invasion and migration of head and neck cancer cells via ERK1/2 activation [53].…”

Section: Discussionmentioning

confidence: 98%

“…Plectin is a protein that is directly linked to cancer and is used as a tumor biomarker in many conditions [51][52][53][54]. Its silencing decreases proliferation, migration and invasion, which is attributed to reduced ERK phosphorylation [50][51][52]54,55].…”

Section: Discussionmentioning

confidence: 99%